NLCP › analyze
NLCP · Analyze
Cannabis net-lease REIT · OTCQX · $15.75 · ~$330M market cap · 20.55M shares · 7 employees Analysis date 2026-08-04 · Held in both accounts
⚠️ This report lands two days before the Q2 2026 print (Thursday Aug 6, 11:00 ET). Every run-rate figure below rests on Q1 2026. The single number that matters on Aug 6 is AFFO/share against $1.75 — the level at which the dividend policy breaks. Treat this verdict as provisional until that print lands.
Verdict — HOLD. Do not add. Conviction 5.0/10
| Verdict | HOLD — covered dividend, deteriorating thesis, no margin of safety |
| Conviction | 5.0 / 10 |
| Fair value | $14.00 – $18.00, central $15.50 – $16.50, scenario-weighted $15.80 |
| Price | $15.75 — 0.3% below weighted fair value |
| Entry zone | $12.50 – $13.50 |
| Trim | $21.00 — ≈10.5x AFFO/sh $2.00 · ≈1.25x marked NAV $16.60 · 8.2% yield |
| Risk rating | Solvent but structurally shrinking. Not a value trap; not cheap. |
The one-sentence read: the dividend is genuinely safe and the business is genuinely deteriorating, and at $15.75 you are paid fair value for both — an 11% coupon with equity risk, no growth, and no discount.
0. What this analysis corrected — read this first
The Watchlist entry for NLCP was factually wrong, and the correction does not change the conclusion.
The standing line read: "Cannabis REIT, 10.90% yield but payout 134%. 🔒 Hold only — do not add until payout normalizes."
| Claimed payout | 134% |
| Source of that number | Yahoo payoutRatio 1.38 = dividends ÷ GAAP EPS |
| True AFFO payout, FY25 | 82% |
| True AFFO payout, Q1'26 | 90% |
analysis_notes.md §4 states outright that "a GAAP-EPS payout ratio on a REIT or BDC is meaningless —
say so rather than reporting it." Knowledge/Playbook/pitfall-vendor-feeds-misread-sales-type-lease-reits.md
carries the same instruction in its guard table. The trap was already documented and it propagated
into a decision artifact anyway, where it stood unchallenged for months.
But correcting it produces no upgrade. The real payout is 90% — which is the ceiling of management's own stated 80–90% target band, arrived at by walking 79% → 82% → 85% → 90% in four quarters. The watchlist reached the right conclusion ("hold only, do not add") through a number that was off by 44 points. A wrong premise that happens to point the right way is not a saved call; it is an unmonitored one. The gate "until payout normalizes" was unfalsifiable, because the metric it named was never going to move.
Three other screen-level numbers on this name are also wrong, all in the bullish direction:
| Screen says | Reality |
|---|---|
| P/B 0.84 — a 16% discount to book | ~0.95x once the three unimpaired vacant buildings are marked. True discount ≈ 5%. |
| Graham IV $22.94 — 46% upside | Discard. Depreciation-depressed EPS, historical-cost BVPS, and a 22.5 constant that embeds a ~7% cost of equity against NLCP's 13–15%. Overstates by ~48%. |
| DYT on full history → $18.20 | Disqualified. The 2021–22 band was set with the 10yr at 1–3%. Every valid band (1yr, 2yr, 3yr, reset peer) brackets or sits below $15.75. |
| Yahoo mean target $17.50 | Unreliable — 2 opinions, includes an unattributable $18, excludes Lucid's $16. Real coverage is 3 boutiques at $16–17. |
Four independent screens say cheap. All four are artifacts. That convergence is itself the finding.
1. The business
NLCP buys the real estate of state-licensed cannabis operators — mostly by sale-leaseback — and leases it back on 15–20 year triple-net terms. The premise is regulatory, and the 10-K says so plainly: the company exists because of "the misalignment of federal and state legislation… the banking industry's general reluctance to finance owners of cannabis-related facilities."
| Portfolio | |
|---|---|
| Properties | 34 (15 cultivation / 19 dispensaries) — 31 leased, 3 vacant |
| Square feet | 1.70M owned · 1.455M leased · 240,419 vacant |
| States | 12 · Top 3 = 65% of ABR (PA 25.1%, FL 20.7%, IL 19.4%) |
| Tenants | 11 · Top 3 = 52.4% of ABR · Top 5 = 70% |
| WALT | 11.9 years — only 0.8% of leases expire through 2029; 57.5% after 2035 |
| Rent escalators | 2.6%/yr |
| Capital deployed | ~$434M · ABR (leased) $47.9M |
| Debt | $7.6M = 1.8% of assets · cash $24.8M · liquidity $107.2M · no maturity until May 2027 |
Two facts the investor deck obscures, and both are load-bearing:
(a) The advertised 13.3% yield is computed on leased assets only. Against the full $434M ever deployed, the realized yield is 11.0%. The 230bp gap is $71.1M of capital — 16.4% of everything the company has ever invested — sitting in three empty greenhouses earning zero.
(b) By invested capital the book is 90.8% cultivation / 9.2% dispensary. The property count (19 dispensaries vs 15 cultivation) makes the portfolio read as retail-weighted and diversified. The dollars are almost entirely in grow facilities. Every problem in this report follows from that line.
The single largest asset is the Curaleaf Mt. Dora, FL cultivation facility — one building, 417,350 SF, $75.98M = 17.5% of all capital ever deployed, and effectively all of Florida's 20.7% of ABR. One tenant, one asset, one state, one regulatory regime ≈ one-fifth of the company.
2. Fundamentals — the annual series says fine, the run-rate says otherwise
Cash earnings (company-reported AFFO — not GAAP, not vendor FCF)
| FY22 | FY23 | FY24 | FY25 | Q1'26 ann. | |
|---|---|---|---|---|---|
| Revenue | $45.00M | $47.30M | $50.13M | $51.07M | $49.24M |
| AFFO | $38.7M | $40.7M | $43.7M | $43.8M | $40.36M |
| AFFO/sh | $1.77 | $1.89 | $2.08 | $2.09 | $1.92 |
| Dividend/sh | $1.44 | $1.57 | $1.70 | $1.72 | $1.72 |
| AFFO payout | 81% | 83% | 82% | 82% | 90% |
| Diluted shares | 21.81M | 21.55M | 20.96M | 20.99M | 21.02M |
| Debt/Assets | 0.66% | 0.46% | 1.76% | 1.81% | 1.6% |
3-year CAGRs (⚠️ NLCP IPO'd Aug 2021 — only four fiscal years exist, so the §1-mandated 5–8yr CAGR is unavailable. Treat every CAGR as low-confidence): Revenue +4.3% · Net income +6.2% · AFFO +4.2% · AFFO/share +5.7% · Diluted shares −1.3%.
The quarterly series is the story
| Q1'25 | Q2'25 | Q3'25 | Q4'25 | Q1'26 | |
|---|---|---|---|---|---|
| Revenue | $13.209M | $12.932M | $12.587M | $12.343M | $12.309M |
| AFFO/sh | $0.51 | $0.55 | $0.52 | $0.51 | $0.48 |
| Dividend/sh | $0.43 | $0.43 | $0.43 | $0.43 | $0.43 |
| AFFO payout | 84% | 79% | 82% | 85% | 90% |
Revenue has fallen five consecutive quarters (−6.8% YoY). AFFO/share is −12.7% off its Q2'25 peak. The payout has walked from 79% to 90% — the ceiling of management's own band — in four quarters.
Why revenue is falling — named and sized
Not a demand-wide reset. Idiosyncratic tenant credit failure, all of it in cultivation.
| Tenant | Properties | Sequence | Annual rent lost |
|---|---|---|---|
| AYR Wellness | Pottsville PA + Sparks NV | Paid through Jul 2025; restructuring support agreement Jul 30 2025; vacated Q3'25; deposits fully consumed by Q4'25 | ~$3.03M |
| Revolutionary Clinics | Fitchburg MA | Paid ~50% of contract rent from Jun 2024; receivership Dec 13 2024; vacated Jul 2025 | ~$2.25M contract |
| Combined vacant ABR | ~$5.3M/yr ≈ 10% of potential |
The Q1'26 rent bridge reconciles exactly: AYR −$757K/qtr + Revolutionary −$281K/qtr = −$1,038K, offset by escalators and two dispensary acquisitions ≈ +$215K → net −$823K, matching the observed $12.586M → $11.763M.
3 of 15 cultivation properties are vacant (20%). 0 of 19 dispensaries are vacant (0%). A new "Property Carrying Costs" line — $232K in Q1'26 — did not exist a year earlier.
Capital allocation — the engine has stalled, and this one is not an artifact
| FY22 | FY23 | FY24 | FY25 | Q1'26 | |
|---|---|---|---|---|---|
| Property acquisitions | $82.2M | $14.8M | $19.1M | $1.49M | $0 |
The pitfall note warns that vendor feeds zero out deployment for sales-type-lease REITs. Checked against the primary cash flow statement — here the stall is real. The $127.1M IPO warchest has been spent to $23.9M. Growth is now capped at ~$4.2M/yr of retained AFFO.
Cumulative FY22–FY25: OCF $162.9M → dividends −$132.5M (81%) · acquisitions −$117.6M · buybacks −$12.1M. Cash fell $127.1M → $23.9M.
The per-share tailwind has stopped. The share count fell 3.8% over three years, entirely on the $11.81M FY23 buyback. Since: $0.253M in FY25, zero in Q1'25 and Q1'26. Diluted count is now rising as stock comp resumes unoffset.
3. Moat — narrow, contractual, time-limited. Not evergreen.
The moat is not regulatory arbitrage. Capital scarcity sets the cap rate; it protects the industry, not NLCP. Sorted against the five sources:
| Source | Present? | |
|---|---|---|
| Network effects | No | Tenants gain nothing from other tenants |
| Cost advantage | Weak/temporary | Real today (unlevered vs IIPR's going-concern language) but replicable by anyone with money |
| Intangibles | Weak | 7 employees. Underwriting relationships are real, thin, and portable — the people are the asset |
| Efficient scale | Partial, exogenous | The smallness is imposed by federal law, not earned |
| Switching costs | Yes — the only genuine one | Cannabis licenses are site-specific. A tenant cannot move a licensed grow to a cheaper building without re-permitting. This is what makes 15–20yr leases at 13% caps enforceable rather than aspirational. |
Named moat: site-specific license switching costs at the property level, priced by an industry-wide regulatory capital shortage. Only the first half is defensible.
And the capital is concentrated in the wrong half of its own moat. The switching-cost moat is strongest where NLCP has the least money — dispensaries, 9.2% of capital, 0% vacant — and weakest where it has the most — cultivation, 90.8% of capital, 20% vacant. That, not rescheduling, is why revenue is falling.
Adversarial stress test
Entry is trivial; the protection is entirely contractual. NLCP runs $417M of assets with 7 people and 1.5% G&A — there is no operating apparatus to defend.
| Attacker | Verdict |
|---|---|
| IIPR (5x larger) | Not a threat — a cautionary tale. Going-concern language, $291.2M of 2026 maturities, multiple tenant defaults, 104% AFFO payout. Scale bought it nothing. |
| Chicago Atlantic (REFI/AFCG) | Real and structurally superior. A ~12% mortgage beats a 13% sale-leaseback for the operator — keeps the upside, keeps the asset. Lenders win the marginal deal as credit improves. |
| Private credit / hedge funds | The core vulnerability. The business needs money, a lawyer, an appraiser, a broker. |
| Regional banks post-SAFER/CLIMB | Extinction-level for new business. Once a licensed operator can get a conventional CRE mortgage, sale-leaseback at 13% is the most expensive money on the table. |
| Tenants refinancing out | Structurally blocked — NLCP's best defense. You cannot refinance out of a building you do not own. |
The asymmetry: the moat dies on the good news
Rescheduling is no longer hypothetical — Schedule III final order, April 22 2026 (medical only). Both incumbents have written down that their advantage is a scarcity rent. NLCP's own 10-K: "Any sustained expansion in operator financing alternatives could increase competition for suitable assets and compress risk-adjusted returns." Chicago Atlantic says the identical thing about the "scarcity premium."
Rescheduling splits the book cleanly:
- The 31 existing leases: unambiguously good. 280E relief lifts tenant cash flow; rent coverage rises; default risk falls. Contract rent is locked 11.9 years at 2.6% escalators — spread compression cannot reach it.
- The reinvestment engine: fatal. New deals price at 8–9% if operators want them at all, which they mostly won't once mortgages exist. The product doesn't get repriced; demand for the structure collapses.
This is a melting ice cube that pays you well while it melts, and the melting accelerates on good news. Both macro paths damage the business: legalization destroys reinvestment economics; continued prohibition destroys the rent roll. There is no macro state in which both halves of the model work at once — which is close to a contradiction, since 280E is the main reason tenants aren't profitable in the first place.
Correct framing: a ~12-year annuity on locked-in above-market rents, unlevered, plus an embedded call option on legalization. That is a legitimate thing to own at the right price. It is not a compounder and must never be sized as one.
The crux — alternative-use value, where 90.8% of the capital sits
| Vacant asset | SF | Invested | $/SF | Net book Q1'26 | Vacant since |
|---|---|---|---|---|---|
| Fitchburg, MA | 145,852 | $42.275M | $290 | $37.070M | Jul 2025 |
| Sparks, NV | 56,536 | $13.579M | $240 | $12.158M | Q3 2025 |
| Pottsville, PA | 38,031 | $15.279M | $402 | $13.712M | Q3 2025 |
| Total | 240,419 | $71.132M | $62.940M | 12+ months, zero rent |
Grows carry specialized HVAC, security and power draw 5–10x conventional warehouse; conversion runs $20–40/SF against generic industrial at $60–120/SF. The buyer pool is only other cannabis operators, and in an oversupplied market incumbents have spare canopy and no reason to bid.
The most informative fact is the twelve months of no transaction. In a functioning market an asset with a real bid clears. A twelve-month failure to clear is not a pricing question — it is a bid existence question.
The market comp confirms it: IIPR sold a 389,000 SF NY grow to Vireo at ~$227/SF in May 2026 — but seller-financed $49M of it at 15%, with Chicago Atlantic funding another $41M. A sale in which the seller funds 55% at distressed rates measures how thin the true bid is; haircut that paper and the cash-equivalent comp is nearer $180–195/SF.
🚩 And NLCP has taken no impairment on any of it. Carrying values decline only via ordinary depreciation. This is permissible because GAAP's recoverability test uses undiscounted future cash flows — an unusually forgiving hurdle. Undiscounted, a building that might someday earn something passes; discounted, it does not. Treat the $62.9M of vacant net book as the softest number on the balance sheet, and do not treat 0.84x stated book as 0.84x real book.
4. Sentiment & regulatory
The catalyst the market is still catching up to: rescheduling already happened
| Date | Event |
|---|---|
| Dec 18 2025 | Trump signs EO 14370 directing the AG to move marijuana to Schedule III |
| Apr 22 2026 | Acting AG Blanche signs a final order under 21 U.S.C. §811(d)(1) — treaty authority, immediate effect, no notice-and-comment. Published FR Apr 28. |
| Apr 23 2026 | Treasury: 280E relief applies to the full taxable year including the effective date → Jan 1 2026 for calendar filers |
| Jun 29 – Jul 15 2026 | Expedited DEA hearing on broader rescheduling before Chief ALJ Derek Julius |
| Aug 17 2026 | Post-hearing briefs due |
What moved: FDA-approved products and marijuana under a qualifying state medical license. What did not: adult-use — even in legal states — still Schedule I. Management says 50–55% of ABR now derives from federally-legal medical activity.
Anyone modelling "if rescheduling happens" is a year behind. What is unpriced is the adult-use leg and retroactive relief.
| Catalyst | Status | Odds | Impact |
|---|---|---|---|
| Medical → Sched III | DONE Apr 22 '26 | 100% | ✅✅ 280E off ~50–55% of rent base |
| DEA grants broader Sched III | Administrator Cole decides; a known skeptic who omitted it from his strategic priorities | ~45% ever | ✅✅✅ The big one |
| D.C. Cir. vacates the April order | 3 petitions consolidated; no stay | ~20% | ❌❌❌ Tail risk — unwinds everything |
| Retroactive 280E relief | Treasury silent; IRS sued TerrAscend 5/18/26 to claw back refunds | ~15% | ✅✅ |
| Hemp THC ban effective | Enacted Nov 2025 approps; live Nov 12 '26 | ~80% | ✅✅ Underrated — kills the unlicensed channel |
| MA Question 8 — repeal adult-use | Certified for the Nov 3 '26 ballot | ~20% | ❌❌ Fitchburg MA becomes unsellable |
| Florida adult-use | Failed to qualify — dead for 2026 | 0% | ❌ Largest conversion prize gone |
| Pennsylvania adult-use | Stalled 3rd year | ~10% | ❌ No catalyst for vacant Pottsville |
| SAFE/SAFER Banking | Refiled Jun '26, zero committee action | ~5% | ✅✅ if ever |
| NLCP uplists | "Engaging exchanges"; no application filed | ~25% | ✅✅✅ Biggest name-specific lever |
The 2026 state slate is defensive for the first time — Florida dead, PA stalled, Massachusetts voting on outright repeal. The growth-by-new-market thesis has stalled.
Tenant P&Ls improved in 2026. Tenant balance sheets did not. All three top tenants cleared their 2026 maturities — Curaleaf ($500M at 11.5% due 2029), Cresco ($325M at 12.5% due 2030), Trulieve (redeemed $368M) — but at 10.5–12.5% coupons versus 8–9.5% before. Refinancing risk is gone; interest burden is permanently higher. That eats part of the 280E windfall before it reaches rent.
Tenant credit — concentration is the risk, not collections
| Tenant | % ABR | Health |
|---|---|---|
| Curaleaf | 25.3% | 🟢 Q1'26 net income $69.8M, refi done |
| Cresco Labs | 15.0% | 🟡 Q1'26 revenue down, net loss $17M, operating cash flow −$5.6M |
| Trulieve | 12.1% | 🟢 Best credit in the book — 59% GM, net cash |
| C3 Industries | 9.5% | 🟢 Private; Hartford CT held for sale, C3 contractually covers any shortfall to basis |
| The Cannabist | 8.1% | 🔴 CCAA Mar 24 '26 + Ch.15 May 9 '26 — still paying full rent. Deposits held $481.6K ≈ 1 month |
| Calypso | 7.8% | 🟠 Missed rent twice in 18mo; security deposit fully drained Feb 2025, no disclosure of replenishment |
| Mint · CODES · Prime Wellness · Acreage · PharmaCann · Budr | 21.5% | Mostly 🟢; Acreage credit upgraded Q1'26 (Holistic + Canopy USA added as guarantors) |
Six of 13 relationships are private companies disclosing no financials at all — 25.4% of ABR is underwritten on data the market cannot verify.
Re-tenanting path for Cannabist is visible: Vireo Growth agreed Jul 20 2026 to buy Cannabist operations in CO, IL, MA, NJ and WV for up to $35M, closing through 2026–27. IL + MA is exactly where NLCP's four Cannabist properties sit. Vireo as successor tenant is a strong inference, not a confirmed fact.
🚩 A disclosure tell worth remembering. NLCP published rent-collection percentages for Q1'25 (98%) and Q1'26 (100%) — and stopped publishing them for exactly the three quarters covering the AYR and Revolutionary Clinics defaults, then resumed at 100%. Note also what "100%" excludes: it is measured against the 31 leased properties. The three dark buildings pay nothing and are not a "collection miss." The entire 6.8% revenue decline lives in that exclusion.
Insider & institutional — the summary field lies
Per pitfall-yahoo-insider-purchases-counts-rsu-grants, transaction rows were read individually.
A portfolio-specific passage was removed from the public build.
🚩 The real insider signal runs the other way. Director David Weinstein — NLCP's former CEO — sold 53,867sh at $20.41–20.84 (Aug '24, ~$1.11M) and 30,253sh at $13.80–14.13 (Aug–Sep '25, ~$424K, at ~74% of book value), received a $60,000 director stock grant on Jun 4 2026, and resigned from the board six weeks later (announced Jul 14–15, effective Jul 31 2026). No reason given, no successor, boilerplate quotes. The board shrank 7 → 6. Take the "no disagreement" language at face value — but a founder-CEO-turned-director selling below book and departing three weeks before an earnings print belongs in the risk column, not the footnotes.
Institutional: Yahoo's 8.3% / 4 institutions is essentially HG Vora alone at 1,615,000 shares = 7.8% (13G/A filed 5/15/26). Filed passive — no 13D, no activist campaign, no strategic-alternatives chatter. HG Vora is activist-capable (it ran the Penn Entertainment campaign); a 13G→13D conversion is worth monitoring, but there is no evidence of one. Yahoo's claimed 18.1% insider vs a 5.2% Section 16 roster sum is unresolved.
Analyst coverage: three boutiques — Lucid $16 (Dec '25), Compass Point $17 (May '26), Zuanic OW no PT. No large-bank coverage, and there won't be until it uplists. The stock at $15.75 is already at or through the low end of real coverage.
5. Valuation
Model selection
| Model | Weight | |
|---|---|---|
| NAV / cap-rate on leased NOI | 40% | The company IS a rent stream plus buildings. Primary anchor. |
| AFFO multiple | 30% | §4: AFFO is the operative REIT metric. Captures G&A drag that asset-NAV ignores. |
| DDM (zero-growth perpetuity) | 20% | Frozen dividend → the perpetuity form is exactly the right shape |
| DYT | 5% | Cross-check only — the naive band fails the rate-regime guard |
| Bogle | 5% | Context, not a fair-value producer |
| Graham IV | 0% — DISCARDED | See §0 |
NAV — the primary anchor
Marking the three vacancies at a blended $95/SF → $23M against $62.9M net book (a $40.1M write-down = $1.91/share), and capitalizing $46.0M of run-rate leased NOI:
| Cap rate | Vacants @ $10M | @ $23M (base) | @ $40M |
|---|---|---|---|
| 13% | $17.70 | $18.32 | $19.14 |
| 14.5% ← base | $15.94 | $16.58 | $17.38 |
| 16% | $14.54 | $15.16 | $15.97 |
Why 14.5%: the book was originated at a 13.3% yield-on-cost in 2019–22 with the 10yr at 1–3%. The 10yr is now 4.70%; holding the risk spread constant would demand ~15.8%. Schedule III is a genuine credit improvement and argues the spread compressed. 14.5% is the midpoint — a judgment, not a comp.
NAV estimate $16.00 – $17.25, central $16.60 — reached independently of, and landing inside, the Moat desk's $16.50–17.50. The 0.84x P/B screen is a mirage: the true discount to marked NAV is ~5%, not 16%.
AFFO multiple, and the cross-check that does not reconcile
| NLCP | IIPR | |
|---|---|---|
| AFFO multiple | 8.20x | 8.02x |
| AFFO payout | 90% | 104% — uncovered |
| Debt/assets | 1.8% | 14.2% |
| Institutional ownership | 8% | 72% |
| YTD 2026 | −1.1% | +26.9% |
| Implied cap rate | 15.87% | 10.79% |
The market pays an identical AFFO multiple for a materially safer balance sheet and a covered dividend. The 508bp cap-rate gap is not explained by fundamentals — it is liquidity and access: 8% institutional versus 72%, ~81K shares/day ≈ $1.3M.
And the discount is self-inflicted. NLCP's 20.6M shares / 18.1M float / $330M cap clear NYSE and NASDAQ listing standards today, and the exchanges plainly accept cannabis landlords — IIPR has been NYSE-listed throughout. The uplist has not happened because management has not done it. Treat it as a free option, not a catalyst to pay for.
⚠️ The denominator is shrinking — the stock gets more expensive by standing still
| AFFO/sh | Multiple at $15.75 | Payout on $1.72 |
|---|---|---|
| $2.09 (FY25) | 7.54x | 82% |
| $1.92 (Q1'26 run-rate) | 8.20x | 90% ← policy ceiling |
| $1.75 | 9.00x | 98% |
| $1.60 | 9.84x | 108% — dividend breaks |
A further 9% decline in AFFO/share breaks the payout policy. That is the entire bear case in one
row, and it is why principle-down-a-lot-is-not-cheap's companion clause applies: a low multiple on
a falling base is not a floor, it is a race.
DYT — the pitfall guard applies, and DYT does not fire
Yahoo's price series is dividend-adjusted (pitfall-adjusted-close-breaks-multiple-bands), so the band
was reconstructed from unadjusted closes plus the full dividend stream.
Decomposition — why is the yield ~11%?
| Window | Yield move | Dividend share | Price share |
|---|---|---|---|
| Trailing 12 months | 12.32% → 10.92% — the yield FELL 140bp | 0% (frozen) | 100% — price +12.7% |
| Since Jan 2022 | 4.92% → 10.92% | 41% | 59% |
| Band | Mean yield | Naive DYT FV |
|---|---|---|
| Full history (2021+) | 9.45% | $18.20 ← contaminated by the 2021 regime |
| 3-year | 10.71% | $16.06 |
| 2-year | 11.13% | $15.45 |
| 1-year | 11.73% | $14.66 |
| Reset to peer class (11–13%) | — | $13.23 – $15.64 |
The four-question guard: why did the yield rise? — over 12 months it fell, on a +12.7% price move. Progressive or formulaic? — frozen, which is a defended dividend but not a growing one. Was the band set in a different regime? — YES, disqualifying. The 2021–22 band (4.9–6.6% yields, $25–30 price) was set with the 10yr at 1–3%, pre-280E relief, pre-shakeout. Does cash cover it? — yes, 1.11x.
DYT verdict: does not fire. Only the stale full-history band produces a buy signal, and it is disqualified. The current yield is below its 1-year mean, below its 2-year mean, and only marginally above its 3-year. The stock is +12% over twelve months and near the top of a $12.09–$16.75 range. This is not a price-collapse yield — it is a yield compressing because the stock rallied.
DDM — and the number that decides this report
Required return built bottom-up, not by CAPM. Per principle-reit-wacc-has-no-tax-shield: a REIT
has no interest tax shield, and beta 0.83 measures the volatility of an 81K-share/day OTCQX mark — it
cannot see 70% tenant concentration, 20% cultivation vacancy, or the absence of an institutional bid.
NLCP has a live $50M ATM, so the primary issuance price is the one that matters.
| Component | bp |
|---|---|
| Risk-free (today's 10yr) | +470 |
| Base equity risk premium | +450 |
| Cannabis tenant credit (20% cultivation default rate in NLCP's own book) | +350 |
| OTCQX illiquidity | +200 |
| Concentration | +125 |
| Less: effectively zero leverage — genuine and large | −175 |
| Required return | ≈14.2% (band 13–15%) |
The backward solve is the finding. At $15.75 with D = $1.72:
| If the market believes… | It is demanding r = |
|---|---|
| g = 0% (frozen forever) | 10.92% |
| g = 1.5% | 12.42% |
| For r = 14.2%, the market must believe | g = 3.28% |
g = 3.28% is not credible — nine quarters frozen, AFFO/sh −6% YoY, escalators 2.6% and being eaten by vacancy, $0 acquisitions in Q1'26, payout at its ceiling.
At $15.75 the market demands a required return of ~10.9–12.4%. The bottom-up build says 13–15%. The market is holding this risk for roughly 150–250bp less than it should demand. Closing that gap alone takes the stock to $13–14.
DDM central range $12.30 – $15.60. Down-weighted to 20% — it ignores $0.20/sh of retained AFFO and gives zero credit to $62.9M of dead book and $107M of liquidity. A floor construction, not a fair value.
Note the spread between asset-NAV ($16.58) and DDM ($13.90). That gap is not noise — it is ~$9M/yr of G&A on a 7-employee company with no growth, capitalized at 13% ≈ $69M ≈ $3.30/share. An asset buyer does not inherit that G&A; a shareholder does.
Bogle expected return (3-year)
| Yield | AFFO/sh growth | Multiple change | Total/yr | |
|---|---|---|---|---|
| Bear | ~8.0% (cut yr 1) | −5.0% | −5.3% | ≈ −4.0% |
| Base | 10.9% | 0.0% | flat | ≈ +10.9% |
| Bull | 10.9% | +4.3% | +10.3% | ≈ +25.5% |
The base case is the dividend and nothing else. That is the honest characterization: a 10.9% coupon with equity risk and no growth attached.
Scenario-weighted fair value
| Scenario | p | FV | |
|---|---|---|---|
| Bear | 30% | $10.50 | Cannabist (8.1% ABR) goes dark → AFFO/sh ~$1.75, payout 98% and breaking → cut to ~$1.25; vacant SF → ~350K with even less bid; re-rates to a 12% yield |
| Base | 50% | $16.50 | Vacancies persist, dividend held, AFFO/sh $1.85–1.95, no acquisitions. NAV at 14.5% cap = $16.58; going-concern at 12.5% AFFO yield = $16.51. Two independent builds within $0.07. |
| Bull | 20% | $22.00 | Adult-use progress re-leases the 240K SF, $107M deployed → AFFO/sh ~$2.19; cap compresses toward 9–10% |
| $15.80 | Weighted — +0.3% vs the $15.75 market price |
Bear at 30% because three things stack: Cannabist is genuinely distressed; the payout is already at its ceiling with only 9% of headroom; and the D.C. Circuit petitions (~20%) would reverse the 280E relief supporting 50–55% of ABR. Tempered by: management has never cut, and the nine-quarter freeze is a defense mechanism that was deliberately deployed and worked.
Bull at 20%, not higher: the adult-use leg is ~45% odds ever, and the re-lease leg is heavily correlated with it — they do not stack independently. Twelve months of failure to clear makes 20% generous.
6. Phase 3 — tensions and how they resolved
| Tension | Resolution |
|---|---|
| Earnings date: Aug 12 vs Aug 5/6 | Aug 6, 11:00 ET. Two desks carried Aug 12 from an aggregator; the company's own 7/14 press release says release Aug 5 after close, call Aug 6. Verified independently. Material — the report lands 2 days early. |
| Is the discount real? Sentiment: "NLCP −1.1% YTD vs IIPR +26.9% — the gap IS the thesis." Valuation: "the discount is permanent; treat it as a free option." | Valuation wins on the evidence, and Sentiment's own research is why. NLCP clears NYSE/NASDAQ standards today and has been OTCQX for five years with no application filed (Sentiment's finding, ~25% odds by 2027). Five years of inaction on the highest-ROI, near-zero-cost action available is revealed management preference, not a constraint. The gap is real and could close — but you do not pay full fair value for an option management has declined to exercise for five years. |
| Dividend stress magnitude: Fundamentals →103% payout; Moat →~97%; Valuation →98% | Spread comes from 9.2% ABR (10-K, 12/31/25) vs 8.1% (Q1'26 deck) and different AFFO bases. Use 8.1% (current): a full Cannabist default puts payout at ~98–103%. Directionally identical across all three — the dividend does not survive it intact. |
| Book value $18.70 vs marked $16.50–17.50 | Moat and Valuation converged independently on ~$16.60–17.00. Marked book is the operative number. Fundamentals took no view on impairment — noted, not a conflict. |
| Watchlist "payout 134%" | Vendor GAAP artifact. Struck. True AFFO payout 90%. All four desks agree. |
No debate round was needed — the disagreements were factual and resolved against primary sources rather than being matters of judgment.
A portfolio-specific passage was removed from the public build.
8. Verdict
HOLD — do not add. Conviction 5.0/10.
At $15.75, scenario-weighted fair value is $15.80. The market is pricing this correctly — arguably under-pricing the risk, since its implied required return (10.9% at g=0) sits 150–250bp below what the risk build supports.
Is the dividend covered? Yes — genuinely, and self-funded. FY25's $35.77M came entirely out of $42.46M of operating cash: no debt drawn, no equity issued, no return of capital. There is no leverage that could force a cut — 1.8% debt/assets, no maturity until May 2027, $107M of liquidity. Nine quarters frozen at $0.43, never cut in company history. The cushion is $0.20/share (10.4% of AFFO) and absorbs a 7.6% loss of current rent.
Is the thesis deteriorating? Yes — clearly, on five independent measures, and per §4 these are different questions with different answers, which must be said outright rather than blended:
- Revenue down five consecutive quarters; AFFO/share −12.7% off its peak.
- ~10% of potential ABR is dark — three cultivation buildings, $71.1M of capital, twelve months with no signed re-lease and management refusing to guide beyond "an uptick in interest."
- Capital deployment has collapsed — $1.49M in FY25, $0 in Q1'26, against $107M of idle liquidity. Growth is capped at ~$4.2M/yr of retained AFFO.
- The per-share tailwind has stopped — buybacks ceased, diluted count rising, $8.2M of authorization unused at 0.84x stated book, while a $50M ATM to issue stays live.
- Concentration is extreme with a visible credit queue — top 5 = 70% of ABR, 92% of rent from cultivation, Cannabist (8.1%) in restructuring, Calypso (7.8%) with a drained deposit.
Point 4 deserves its own sentence. Buying back stock at $15.75 is a ~12.2% return with zero execution risk. Issuing equity at that price to buy assets at a 13% cap is barely accretive and dilutive to NAV. Management is choosing the worse trade — and running an issuance program and a repurchase program simultaneously, using only the one that destroys value. That is a permanent haircut to the multiple, not a passing complaint.
Is 11% adequate compensation? Not at $15.75. The yield is being asked to pay for a rent roll down five quarters, a payout at its policy ceiling with 9% of headroom, $62.9M of net book earning zero and unimpaired only via an undiscounted test, 70% top-5 concentration, zero growth capital deployed, and 8% institutional ownership that management is not fixing. Priced honestly, that is a 13% asset — which is roughly $13.
The offset is real and will not be understated: effectively no debt, no maturity to May 2027, an 11.9-year WALT with 0.8% expiring through 2029, zero dispensary vacancy, a dividend never cut, and 280E relief now live on 50–55% of ABR. This is not a value trap. It is a genuinely solvent company that cannot be forced to do anything. It simply is not cheap.
And the two cases are not mutually exclusive — they are the same forecast valued over different horizons. If the adult-use leg lands, tenant credit repairs faster than cultivation vacancy bleeds, the book re-rates from 13% toward 9% caps, and the stock works very well even as the business becomes structurally obsolete. That is the correct way to hold it: a ~12-year annuity plus a call option, sized as neither a compounder nor a bond.
Actions
| Self (14sh, $220) | Hold. Flag to /rebalance as a fragmentation candidate — half an average position, 5.0 conviction, no add case. |
| Beta (120sh, $1,890) | Hold. Do not add. Defensible size for what it is. |
| Entry | $12.50 – $13.50 (13.2% yield, 6.8x AFFO, 21% discount to marked NAV). Reachable without catastrophe — $12.90 printed Nov 2025, $13.30 in Apr 2026. Set an alert at $13.50. |
| Trim | $21.00 — ≈10.5x AFFO/sh $2.00, ≈1.25x marked NAV, 8.2% yield. Only reachable in the bull case, which is correct: trim into rescheduling euphoria, not before. |
⚠️ The trim must NOT be written as a bare multiple — this would invert the recommendation
The site derives multiple-trims off GAAP EPS. For NLCP, GAAP EPS (ttm) is $1.25 against AFFO/sh
of $1.92 — 54% higher. A 10x trim would render as $12.50 — below the current price and below
the entry zone, painting a permanent standing "TRIM NOW" on a name we are telling the user to
accumulate 15% lower. Use the ARCC precedent: a dollar figure with the multiple judgment written out
beside it. Do not write a bare multiple for this ticker until the site accepts an explicit AFFO
denominator.
9. Recheck & triggers
recheck: 2026-08-06 · decay: fast — the Q2 print is 2 days out and this verdict is provisional
until it lands.
| Watch on Aug 6 | Why |
|---|---|
| AFFO/share vs $1.75 | The payout-break line. Below ~$0.45/qtr and the 80–90% band is gone. |
| Any re-tenanting of Pottsville / Sparks / Fitchburg | $71.1M of dead capital. A signed lease is the single biggest positive surprise available. |
| Calypso — deposit replenished? | 7.8% of ABR with zero collateral since Feb 2025 |
| Cresco — four-wall coverage | 15% of ABR with negative operating cash flow |
| Cannabist / Vireo — lease assumption, economics, timing | 8.1% of ABR; only ~1 month of deposits held |
| Buyback — any Q2 repurchases against the $8.2M | The capital-allocation tell |
| Uplisting — "engaging" → an actual application | The largest name-specific lever, ~25% odds |
Other dated triggers: DEA post-hearing briefs Aug 17 2026 · MA Question 8 ballot Nov 3 2026 · hemp THC ban effective Nov 12 2026 · D.C. Circuit petitions 2027.
Break triggers (thesis void, not merely stale): AFFO payout >100% for two quarters · any base dividend cut · a second tenant default >5% of ABR · impairment taken on the vacant portfolio · D.C. Circuit vacating the April 2026 rescheduling order.
10. Data gaps — declared
- Q2 2026 results not yet reported (Aug 6). All run-rate math rests on Q1 2026. The only Q2 datapoints are the held $0.43 dividend and "100% of contractual rent collected" — phrasing that excludes the three dark buildings.
- Total ABR is never disclosed as a discrete figure. The $52.3M full-occupancy estimate is derived.
- Per-property rent is not disclosed. AYR's ~$3.03M and Revolutionary's ~$2.25M are inferred from security-deposit application and a 50% stub. Estimates, not filed figures.
- No independent appraisal exists for the three vacant properties. The $95/SF base mark is a reasoned range, not a mark.
- 25.4% of ABR sits with private tenants disclosing no financials at all.
- No revolver covenant package found beyond the ≤50%-of-tangible-asset-cost investment guideline. The $82.4M of "undrawn capacity" is collateral-conditioned — it shrinks precisely when vacancy rises, i.e. exactly when it would be needed.
- No 2026 guidance issued. Management declined re-leasing timing on the Q1'26 call.
- 5–8yr CAGRs are impossible — NLCP IPO'd Aug 2021. Every CAGR here is 3-year.
- Yahoo's 18.1% insider vs a 5.2% Section 16 roster sum is unresolved.
- SEC EDGAR returned HTTP 403 to automated fetching throughout; filing content came via ir.newlake.com, the company's investor deck, and filing-summary aggregators — one layer removed from raw EDGAR.
- 🚩 No
/macrorun has ever been done. PerKnowledge/Themes/reits.md, this has been the binding constraint on this field since April. The 14.5% cap rate and the 13–15% required return are reasoned judgments unanchored to any observed cannabis-real-estate transaction market. A ±100bp cap-rate error moves NAV by ±$1.05/share — larger than the entire margin over the current price. This report's central conclusion is robust in direction and fragile in magnitude.
Sources
Company: FY2025 10-K · Q1'26 10-Q · Q1'26 Investor Presentation · Q1 2026 results · Q1'26 earnings call transcript · FY2025 results · Q2'26 dividend, Jun 12 2026 · Q2'26 earnings call date, Jul 14 2026 · 8-K Weinstein board resignation · Board transition PR
Regulatory: DOJ — Schedule III final order · Federal Register 2026-08177 · EO 14370 · Treasury — 280E timing · Vicente LLP — economic impact · Akerman — rescheduled but not listed · Marijuana Moment — DEA administrator priorities
Tenants & peers: Curaleaf $500M refi · Cresco $325M refi · Trulieve note redemption · Vireo acquires Cannabist assets · IIPR Q1'26 10-Q · IIPR–Vireo NY facility sale · REFI second-lien financing · REFI–LIEN merger · Cannabis facility conversion costs
Internal: analysis_notes.md §1–§5 · Knowledge/Playbook/pitfall-vendor-feeds-misread-sales-type-lease-reits.md ·
principle-reit-wacc-has-no-tax-shield.md · pitfall-dyt-inverts-when-price-caused-the-yield.md ·
principle-down-a-lot-is-not-cheap.md · pitfall-yahoo-insider-purchases-counts-rsu-grants.md ·
pitfall-adjusted-close-breaks-multiple-bands.md · Knowledge/Themes/reits.md ·
Knowledge/Portfolio/self-state.md · Yahoo Finance MCP · .mcp/fin.py NLCP